

Boehringer Ingelheim targets medical breakthroughs with Google Quantum AI

11 January 2021 | News

Boehringer Ingelheim is the first pharmaceutical company worldwide to join forces with Google in quantum computing



Boehringer Ingelheim (BI) has announced a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations.

The new partnership combines Boehringer Ingelheim's leading expertise in the field of computer-aided drug design and in silico modeling with Google's outstanding resources as one of the leading developers of quantum computers and algorithms.

Boehringer Ingelheim is the first pharmaceutical company worldwide to join forces with Google in quantum computing. The partnership is designed for three years and is co-led by the newly established Quantum Lab of Boehringer Ingelheim.

"We are really excited about joining forces with Google, the leading tech company when it comes to quantum computing," says Michael Schmelmer, Member of the Board of Managing Directors, Boehringer Ingelheim with responsibility for Finance and Corporate Functions.

The new collaboration is part of Boehringer Ingelheim's comprehensive digital transformation strategy with the aim to better leverage and accelerate the company's promising pipeline and ultimately bringing more medical breakthroughs to patients in need.

"Boehringer Ingelheim brings both an impressive quantum computing team and deep expertise in real world applications of these capabilities in the pharmaceuticals space," says Ryan Babbush, Head, Quantum Algorithms, Google.

Michel Pairet, Member of the Board of Managing Directors, Boehringer Ingelheim with responsibility for the company's Innovation Unit said, "Together with Google, our goal is to apply the use of quantum computing in biopharmaceutical R&D and thus continue to make a decisive contribution to medical progress for patients around the world."

We are looking forward to jointly working on the field with fundamental research and a joint vision for solving relevant pharma

problems in the beyond-classical regime over the next decade,” says Markus Hoffmann, Google Quantum AI Partnerships.